Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that both topiramate and divalproex sodium were similarly effective in reducing headache frequency by over 50% among episodic migraine patients after three months of treatment.

This case report describes a woman who experienced complete but temporary scalp hair loss after a massive overdose of divalproex, suggesting a potential acute side effect of the drug.

This study observed that propranolol, flunarizine, and divalproex sodium were equally effective in managing migraine across a three-month period in a group of 84 patients, with various side effects noted among the drug groups.

This case report from the University of Alabama, Birmingham describes a rare paradoxical reaction of increased agitation and hyperactivity in a patient with schizoaffective disorder treated with divalproex sodium.

This case report from the University of Alabama describes a rare paradoxical effect where divalproex sodium was associated with increased agitation and hostility in a patient with schizoaffective disorder.

This study suggests that low alternating daily doses of sodium divalproate may be effective for migraine prevention, similarly to higher doses, but can still lead to modest weight gain.

In this case report, a young male developed bilateral pleural effusion and persistent fever after starting divalproex sodium for bipolar disorder, which improved upon discontinuation of the drug, suggesting a possible link between divalproex sodium and pleural effusion.

In this study, divalproex sodium extended-release was found to be more tolerable and preferred by patients compared to the delayed-release formulation, with improved seizure control and psychiatric symptom relief.

In this study, patients with epilepsy who switched from immediate-release to extended-release divalproex sodium did not experience significant changes in seizure frequency, but most preferred the new formulation due to a subjective decrease in tremor during daily activities.

In this study, two-thirds of patients with persistent chronic daily headache significantly improved with divalproex sodium treatment, while liver functions remained unaffected.

This review discusses the potential for mood stabilizers, antidepressants, and some antipsychotic and antianxiety drugs to induce alopecia and reports no clinical results.

This article reviews the association between psychopharmaceuticals and medication-induced alopecia, noting that hair regrowth typically occurs after discontinuing or reducing the medication, while mineral supplements' effectiveness remains unclear.

This study found that two-thirds of patients with persistent chronic daily headache showed significant improvement with divalproex sodium treatment, although common side effects included weight gain, tremor, hair loss, and nausea.

This report describes a case where hidradenitis suppurativa developed in a patient receiving lithium, adding to the recognized cutaneous side effects like psoriasis, acneiform lesions, and alopecia.

This review discusses the challenges of diagnosing and treating pediatric bipolar disorder and highlights the potential benefits of combined psychopharmacological treatments, noting no long-term efficacy from mood stabilizer monotherapy.

This report describes a potential association between HAIR-AN syndrome and the onset of manic symptoms in a patient after discontinuing oral contraceptives, though this relationship requires further investigation.

This review discusses various psychiatric treatments including antipsychotics, insomnia medication, and mood stabilizers, but reports no new clinical results; the authors comment on existing findings and approvals.

This study found that valproic acid is effective in controlling absence seizures and can improve other seizure types, but 20% of patients experience mostly transient adverse reactions.

This study reports that valproic acid is effective in treating absence seizures and shows improvement in other types of seizures, though about 20% of patients experienced adverse effects.

This review highlights valproic acid's efficacy and tolerability as a first-line treatment for various seizure types in both adults and children, emphasizing its minimal neurological adverse effects compared to other antiepileptic drugs.

In this study, sustained-release sodium valproate showed high efficacy in achieving seizure remission for adults with focal and generalized epilepsy over one year, but side effects like weight gain and tremor were more frequent among heterozygous carriers of certain gene variants.

Sodium valproate can worsen psoriasis-like skin conditions.

This article reviews the uses, mechanisms, and side effects of valproate in treating bipolar disorder, noting its first-line status for several manic conditions but also highlighting serious risks such as fetal abnormalities.

This review compiles recent findings on the pharmacokinetics, pharmacodynamics, and pharmacogenomics of Valproate, highlighting potential new uses, benefits, and risks, but reports no new clinical results.

This study found that sodium valproate significantly reduced seizure frequency by over 50% in about 70% of patients with generalized seizures but was less effective for partial seizures.

In this study, sodium valproate achieved complete seizure control in 82% of children as monotherapy, with higher plasma levels potentially linked to resistant cases.

This study found that valproate sustained-release monotherapy provided effective short-term seizure control and was well tolerated in newly-diagnosed epileptic patients with partial seizures in the Gulf Cooperation Council countries.

This study reported that extended-release valproate significantly reduced seizure frequency and improved quality of life in epilepsy patients over six months, despite some adverse effects like weight gain and tremor.

This case report describes a 31-year-old male who developed eosinophilic pleuropericardial effusion potentially linked to long-term valproic acid use, which resolved after adjusting his medication.

This review discusses the development of valproate as an effective monotherapy for controlling generalized seizures and reports no new clinical results.